Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
KANTOFF, Philip W, SCHUETZ, Thomas J, DAHUT, William L, ARLEN, Philip M, GULLEY, James L, GODFREY, Wayne R, BLUMENSTEIN, Brent A, GLODE, L. Michael, BILHARTZ, David L, WYAND, Michael, MANSON, Kelledy, PANICALI, Dennis L, LAUS, Reiner, SCHLOM, Jeffrey
Published in Journal of clinical oncology (01.03.2010)
Published in Journal of clinical oncology (01.03.2010)
Get full text
Journal Article
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, Ajay K, Kahl, Brad S, de Vos, Sven, Wagner-Johnston, Nina D, Schuster, Stephen J, Jurczak, Wojciech J, Flinn, Ian W, Flowers, Christopher R, Martin, Peter, Viardot, Andreas, Blum, Kristie A, Goy, Andre H, Davies, Andrew J, Zinzani, Pier Luigi, Dreyling, Martin, Johnson, Dave, Miller, Langdon L, Holes, Leanne, Li, Daniel, Dansey, Roger D, Godfrey, Wayne R, Salles, Gilles A
Published in The New England journal of medicine (13.03.2014)
Published in The New England journal of medicine (13.03.2014)
Get full text
Journal Article
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Kahl, Brad S., Spurgeon, Stephen E., Furman, Richard R., Flinn, Ian W., Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Peterman, Sissy, Cho, Yoonjin, Yu, Albert, Godfrey, Wayne R., Wagner-Johnston, Nina D.
Published in Blood (29.05.2014)
Published in Blood (29.05.2014)
Get full text
Journal Article
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Fowler, Nathan H., Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jacqueline C., Rai, Kanti R., Boyd, Thomas E., Furman, Richard R., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.
Published in Blood advances (13.12.2016)
Published in Blood advances (13.12.2016)
Get full text
Journal Article
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Flinn, Ian W., Kahl, Brad S., Leonard, John P., Furman, Richard R., Brown, Jennifer R., Byrd, John C., Wagner-Johnston, Nina D., Coutre, Steve E., Benson, Don M., Peterman, Sissy, Cho, Yoonjin, Webb, Heather K., Johnson, David M., Yu, Albert S., Ulrich, Roger G., Godfrey, Wayne R., Miller, Langdon L., Spurgeon, Stephen E.
Published in Blood (29.05.2014)
Published in Blood (29.05.2014)
Get full text
Journal Article
NF90 regulates inducible IL-2 gene expression in T cells
Shi, Lingfang, Godfrey, Wayne R, Lin, Joseph, Zhao, Guohua, Kao, Peter N
Published in The Journal of experimental medicine (14.05.2007)
Published in The Journal of experimental medicine (14.05.2007)
Get full text
Journal Article
In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures
Godfrey, Wayne R., Ge, Ying G., Spoden, Darrin J., Levine, Bruce L., June, Carl H., Blazar, Bruce R., Porter, Stephen B.
Published in Blood (15.07.2004)
Published in Blood (15.07.2004)
Get full text
Journal Article
Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function
Godfrey, Wayne R., Spoden, Darrin J., Ge, Ying G., Baker, Seth R., Liu, Baoling, Levine, Bruce L., June, Carl H., Blazar, Bruce R., Porter, Stephen B.
Published in Blood (15.01.2005)
Published in Blood (15.01.2005)
Get full text
Journal Article
Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40)
Pippig, Susanne D, Pena-Rossi, Claudia, Long, James, Godfrey, Wayne R, Fowell, Deborah J, Reiner, Steven L, Birkeland, Marian L, Locksley, Richard M, Barclay, A. Neil, Killeen, Nigel
Published in The Journal of immunology (1950) (15.12.1999)
Published in The Journal of immunology (1950) (15.12.1999)
Get full text
Journal Article
NF90 Regulates Cell Cycle Exit and Terminal Myogenic Differentiation by Direct Binding to the 3′-Untranslated Region of MyoD and p21WAF1/CIP1 mRNAs
Shi, Lingfang, Zhao, Guohua, Qiu, Daoming, Godfrey, Wayne R., Vogel, Hannes, Rando, Thomas A., Hu, Hong, Kao, Peter N.
Published in The Journal of biological chemistry (13.05.2005)
Published in The Journal of biological chemistry (13.05.2005)
Get full text
Journal Article
Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323)
Keyt, Bruce, Baliga, Ramesh, Li, Keyu, Manlusoc, Marigold, Hinton, Paul, Ng, Dean, Tran, Madeline, Shan, Bing, Lu, Hai, Rahman, Sachi, Saini, Avneesh, Cao, Yuan, Saraiya, Chitra, Peterson, Marvin, Godfrey, Wayne R, Carroll, Steve
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Gopal, Ajay K., Kahl, Brad S., de Vos, Sven, Wagner-Johnston, Nina D., Schuster, Stephen J., Jurczak, Wojciech, Flinn, Ian W., Flowers, Christopher R., Martin, Peter, Viardot, Andreas, Blum, Kristie A., Goy, Andre, Davies, Andrew, Zinzani, Pier Luigi, Dreyling, Martin H., Holes, Leanne M., Sorensen, Bess, Godfrey, Wayne R., Salles, Gilles Andre
Published in Blood (06.12.2014)
Published in Blood (06.12.2014)
Get full text
Journal Article
Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results
de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian, Schreeder, Marshall T., Fowler, Nathan, Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jaqueline C., Rai, Kanti R., Boyd, Thomas E, Furman, Richard R., Holes, Leanne M., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.
Published in Blood (06.12.2014)
Published in Blood (06.12.2014)
Get full text
Journal Article
Reply to L. León et al
Kantoff, Philip W., Blumenstein, Brent A., Gulley, James L., Godfrey, Wayne R.
Published in Journal of clinical oncology (20.08.2010)
Published in Journal of clinical oncology (20.08.2010)
Get full text
Journal Article
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)
De Vos, Sven, Sehn, Laurie Helen, Mulligan, Stephen P., Dreyling, Martin H., Rummel, Mathias J., Zinzani, Pier Luigi, Johnson, David Michael, Evans, Shelley, Dansey, Roger D., Godfrey, Wayne R., Czuczman, Myron Stefan
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer
McLeod, David G., Adams, George W., Gittleman, Marc C., Bihartz, David L., Reiling, Richard B., Ruiz, Henry E., Cochran, James S., Prettyman, Julie, Delcayre, Alain, Godfrey, Wayne R., Legrand, Fatema A., Mann, Grace, Bandman, Olga
Published in Journal of clinical oncology (20.02.2013)
Published in Journal of clinical oncology (20.02.2013)
Get full text
Journal Article
Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Gopal, Ajay, Kahl, Brad S., De Vos, Sven, Wagner-Johnston, Nina D., Schuster, Stephen J., Blum, Kristie A., Jurczak, Wojciech J., Flinn, Ian W., Flowers, Christopher R., Martin, Peter, Viardot, Andreas, Goy, Andre, Davies, Andrew, Zinzani, Pier Luigi, Dreyling, Martin H., Holes, Leanne M., Li, Daniel, Dansey, Roger, Godfrey, Wayne R., Salles, Gilles A.
Published in Blood (15.11.2013)
Published in Blood (15.11.2013)
Get full text
Journal Article
Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)
Spurgeon, Stephen Edward Forbes, Wagner-Johnston, Nina D., Furman, Richard R., Flinn, Ian, Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Leonard, John, Peterman, Sissy, Johnson, David Michael, Gu, Jessie, Dansey, Roger D., Godfrey, Wayne R., Kahl, Brad S.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article